{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:22:02Z","timestamp":1790698922283,"version":"4.1.0"},"reference-count":57,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal of Australia"],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The main mission of the Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG) is to develop and facilitate local access to the world's leading evidence\u2010based clinical trials for all paediatric cancers, including brain tumours, as soon as practically possible. Diffuse intrinsic pontine gliomas (DIPGs) \u2014 a subset of a larger group of tumours now termed diffuse midline glioma, H3K27\u2010altered (DMG) \u2014 are paediatric brain cancers with less than 10% survival at two years. In the absence of any proven curative therapies, significant recent advancements have been made in pre\u2010clinical and clinical research, leading many to seek integration of novel therapies early into standard practice. Despite these innovative therapeutic approaches, DIPG remains an incurable disease for which novel surgical, imaging, diagnostic, radiation and systemic therapy approaches are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main recommendations<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>All patients with DIPG should be discussed in multidisciplinary neuro\u2010oncology meetings (including pathologists, neuroradiologists, radiation oncologists, neurosurgeons, medical oncologists) at diagnosis and at relapse or progression.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Radiation therapy to the involved field remains the local and international standard of care treatment.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Proton therapy does not yield a superior survival outcome compared with photon therapy and patients should undergo radiation therapy with the available modality (photon or proton) at their treatment centre.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Patients may receive concurrent chemotherapy or radiation\u2010sensitising agents as part of a clinical trial.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Biopsy should be offered to facilitate consideration of experimental therapies and eligibility for clinical trial participation.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>After radiation therapy, each patient should be managed individually with either observation or considered for enrolment on a clinical trial, if eligible, after full discussion with the family.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Re\u2010irradiation can be considered for progressive disease.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Changes in management as a result of the guideline<\/jats:title>\n                    <jats:p>Every child diagnosed with DIPG should be offered enrolment on a clinical trial where available. Access to investigational drugs without biological rationale outside the clinical trial setting is not supported. In case of potentially actionable target identification with molecular profiling and absence of a suitable clinical trial, rational targeted therapies can be considered through compassionate access programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5694\/mja2.52295","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T05:36:45Z","timestamp":1714714605000},"page":"533-538","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children's Haematology\/Oncology Group position statement"],"prefix":"10.5694","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9655-0001","authenticated-orcid":false,"given":"Santosh","family":"Valvi","sequence":"first","affiliation":[{"name":"Perth Children's Hospital  Perth WA"},{"name":"Telethon Kids Institute  Perth WA"},{"name":"University of Western Australia  Perth WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neevika","family":"Manoharan","sequence":"additional","affiliation":[{"name":"Kids Cancer Centre, Sydney Children's Hospital  Randwick Sydney NSW"},{"name":"University of New South Wales  Sydney NSW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2763-5853","authenticated-orcid":false,"given":"Marion K","family":"Mateos","sequence":"additional","affiliation":[{"name":"Kids Cancer Centre, Sydney Children's Hospital  Randwick Sydney NSW"},{"name":"University of New South Wales  Sydney NSW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-3710","authenticated-orcid":false,"given":"Timothy EG","family":"Hassall","sequence":"additional","affiliation":[{"name":"Queensland Children's Hospital  Brisbane QLD"},{"name":"Frazer Institute, University of Queensland  Brisbane QLD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Ziegler","sequence":"additional","affiliation":[{"name":"Kids Cancer Centre, Sydney Children's Hospital  Randwick Sydney NSW"},{"name":"University of New South Wales  Sydney NSW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey B","family":"McCowage","sequence":"additional","affiliation":[{"name":"Children's Hospital at Westmead  Sydney NSW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Dun","sequence":"additional","affiliation":[{"name":"University of Newcastle  Newcastle NSW"},{"name":"Hunter Medical Research Institute  Newcastle NSW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D","family":"Eisenstat","sequence":"additional","affiliation":[{"name":"Children's Cancer Centre Royal Children's Hospital Melbourne  Melbourne VIC"},{"name":"Murdoch Children's Research Institute  Melbourne VIC"},{"name":"University of Melbourne  Melbourne VIC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G","family":"Gottardo","sequence":"additional","affiliation":[{"name":"Perth Children's Hospital  Perth WA"},{"name":"Telethon Kids Institute  Perth WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan R","family":"Hansford","sequence":"additional","affiliation":[{"name":"Women's and Children's Hospital  Adelaide SA"},{"name":"South Australian Health and Medical Research Institute  Adelaide SA"},{"name":"University of Adelaide  Adelaide SA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"e_1_2_9_1_1","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2013.194"},{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq205"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00572-5"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70615-5"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.9308"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24730"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-008-9525-5"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-029"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.04.031"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-011-0681-7"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now038"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24060"},{"key":"e_1_2_9_14_1","first-page":"1","article-title":"Stereotactic biopsy of diffuse pontine lesions in children","volume":"107","author":"Roujeau T","year":"2007","journal-title":"J Neurosurg"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5677"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.713"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9119"},{"key":"e_1_2_9_18_1","first-page":"vdad024","article-title":"HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma","volume":"5","author":"Wang SS","year":"2023","journal-title":"Neurooncol Adv"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad141"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0186"},{"key":"e_1_2_9_21_1","volume-title":"The RAND\/UCLA appropriateness method user's manual","author":"Fitch K","year":"2001"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010219"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-019-0577-y"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-023-06037-5"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30166-2"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa140"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor076"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002470050418"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06114-6"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1448-8"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3171\/2019.5.PEDS18376"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073815601495"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3171\/2017.2.PEDS1665"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos330"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005658"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-03038-2"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/bio.2019.0013"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2363-y"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2372-5"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100846"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4889"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.14791\/btrt.2022.0041"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-019-04420-9"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.01.054"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npaa063"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26988"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00237"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa222.100"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000142076.52721.b3"},{"key":"e_1_2_9_50_1","first-page":"vdac100","article-title":"Does a Bevacizumab\u2010based regime have a role in the treatment of children with diffuse intrinsic pontine glioma? A systematic review","volume":"4","author":"Evans M","year":"2022","journal-title":"Neurooncol Adv"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29061"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00009-7"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00070-0"},{"key":"e_1_2_9_54_1","first-page":"vdab169","article-title":"Preclinical and clinical evaluation of German\u2010sourced ONC201 for the treatment of H3K27M\u2010mutant diffuse intrinsic pontine glioma","volume":"3","author":"Duchatel RJ","year":"2021","journal-title":"Neurooncol Adv"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.01.015"},{"key":"e_1_2_9_56_1","first-page":"vdab087","article-title":"Parents\u2019 experiences of postmortem tumor donation for high\u2010grade gliomas: benefits and suggested improvements","volume":"3","author":"Robertson EG","year":"2021","journal-title":"Neurooncol Adv"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-019-03302-z"}],"container-title":["Medical Journal of Australia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.5694\/mja2.52295","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.5694\/mja2.52295","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.5694\/mja2.52295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T10:27:26Z","timestamp":1772965646000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.5694\/mja2.52295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,6,3]]}},"alternative-id":["10.5694\/mja2.52295"],"URL":"https:\/\/doi.org\/10.5694\/mja2.52295","archive":["Portico"],"relation":{},"ISSN":["0025-729X","1326-5377"],"issn-type":[{"value":"0025-729X","type":"print"},{"value":"1326-5377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"2023-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}